Data Sheet 5_Effects of aging on otolith morphology and functions in mice.xlsx by Keita Ueda (19855536)

“…Background<p>Increased fall risk caused by vestibular system impairment is a significant problem associated with aging. …”

Data Sheet 4_Effects of aging on otolith morphology and functions in mice.xlsx by Keita Ueda (19855536)

“…Background<p>Increased fall risk caused by vestibular system impairment is a significant problem associated with aging. …”

Data Sheet 3_Effects of aging on otolith morphology and functions in mice.xlsx by Keita Ueda (19855536)

“…Background<p>Increased fall risk caused by vestibular system impairment is a significant problem associated with aging. …”

Data Sheet 8_Effects of aging on otolith morphology and functions in mice.xlsx by Keita Ueda (19855536)

“…Background<p>Increased fall risk caused by vestibular system impairment is a significant problem associated with aging. …”

Data Sheet 1_Effects of aging on otolith morphology and functions in mice.docx by Keita Ueda (19855536)

“…Background<p>Increased fall risk caused by vestibular system impairment is a significant problem associated with aging. …”

Data Sheet 1_The relationship between hearing loss and frailty in older adults at risk of cognitive decline: a cross-sectional study.pdf by Rong Tian (397491)

“…Objectives<p>To investigate the association between hearing loss and frailty among a group of older community volunteers with mild cognitive impairment.</p>Design<p>This study recruited 162 older community volunteers who have mild cognitive impairment and symmetric age-related hearing loss. …”

Image 1_Cerebellar microstructural and functional connectivity changes in patients with neuromyelitis optica spectrum disorders and their correlation with cognitive function: a fem... by Yingyu Zhang (7846409)

“…</p>Results<p>Patients exhibited significant cerebellar alterations, including GMV reduction in bilateral lobules VI/VIII and the vermis, decreased fractional anisotropy in Crus I, and altered FC between Crus I and occipital/frontal regions. …”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Data Sheet 1_Breaking the cycle: a pilot study on autonomous Digital CBTe for recurrent binge eating.pdf by Rebecca Murphy (5514419)

“…Those who completed all sessions and the post-intervention assessment (n = 55, 50%) reported significant decreases in binge eating, eating disorder psychopathology, and secondary impairment at post-intervention. …”

Data Sheet 4_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 3_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 2_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 1_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Table 2_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS and OM can cause severe discomfort and functional impairment. …”

Data Sheet 2_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”

Data Sheet 1_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”